ArticleBritish journal of pharmacology2002
Rolipram inhibits leukocyte-endothelial cell interactions in vivo through P- and E-selectin downregulation.
Article in British journal of pharmacology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 42 citations in OpenAlex.
- Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases.International journal of molecular sciences · 2021Review
- Type-4 Phosphodiesterase (PDE4) Blockade Reduces NETosis in Cystic Fibrosis.Frontiers in pharmacology · 2021Article
- PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue.International journal of molecular sciences · 2017Review
- The future of EPAC-targeted therapies: agonism versus antagonism.Trends in pharmacological sciences · 2015Review
- Phosphodiesterase type 4 blockade prevents platelet-mediated neutrophil recruitment at the site of vascular injury.Arteriosclerosis, thrombosis, and vascular biology · 2014Article
- Rolipram attenuates bile duct ligation-induced liver injury in rats: a potential pathogenic role of PDE4.The Journal of pharmacology and experimental therapeutics · 2013Article
- Phosphodiesterase inhibitor improves renal tubulointerstitial hypoxia of the diabetic rat kidney.The Korean journal of internal medicine · 2012Article
- Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease.British journal of pharmacology · 2009Review
- Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability.British journal of pharmacology · 2007Article
- Compound Danshen injection improves endotoxin-induced microcirculatory disturbance in rat mesentery.World journal of gastroenterology · 2007Article
- A small molecule, orally active, alpha4beta1/alpha4beta7 dual antagonist reduces leukocyte infiltration and airway hyper-responsiveness in an experimental model of allergic asthma in Brown Norway rats.British journal of pharmacology · 2006Article
- Suppressive effect of phosphodiesterase type 4 inhibition on systemic inflammatory responses after cardiopulmonary bypass.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2006Article
- Phosphodiesterase 4D and 5-lipoxygenase activating protein in ischemic stroke.Annals of neurology · 2005Article
- Erythromycin exerts in vivo anti-inflammatory activity downregulating cell adhesion molecule expression.British journal of pharmacology · 2005Article
- Impaired host defense to Klebsiella pneumoniae infection in mice treated with the PDE4 inhibitor rolipram.British journal of pharmacology · 2003Article
- Effect of two phenanthrene alkaloids on angiotensin II-induced leukocyte-endothelial cell interactions in vivo.British journal of pharmacology · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1. Rolipram, a selective phosphodiesterase (PDE) type 4 inhibitor, was used to characterize leukocyte recruitment mechanisms in models of acute and subacute inflammation. Intravital microscopy within the rat mesenteric microcirculation was employed. 2. Mesentery superfusion with PAF (0.1 microM) induced a significant increase in leukocyte rolling flux, adhesion and emigration at 60 min. Rolipram pretreatment, markedly inhibited these parameters by 100, 95 and 95% respectively. 3. Similar effects were observed when the mesentery was superfused with LPS (1 microg ml(-1)) for the same time period and these leukocyte parameters were nearly abrogated by rolipram pretreatment. 4. LPS exposure of the mesentery for 4 h caused a greater increase in leukocyte rolling flux, adhesion and emigration which were inhibited by rolipram administration by 51, 71 and 81% respectively. 5. Immunohistochemistry revealed a significant increase in P-selectin expression after 60 min superfusion with PAF which was attenuated by rolipram. 6. LPS exposure of the mesentery for 4 h caused a significant increase in P- and E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) expression. Rolipram pretreatment down-regulated both P- and E-selectin expression but had no effect on ICAM-1 and VCAM-1 expression. 7. Significant increases in plasma cyclic AMP levels were detected at 4.5 h after rolipram administration. 8. In conclusion, we have demonstrated that rolipram is a potent in vivo inhibitor of leukocyte-endothelial cell interactions. The effects observed are mediated through endothelial P- and E-selectin downregulation. Therefore, selective PDE-4 inhibitors may be useful in the control of different inflammatory disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.